psychedelics-investing MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics
psychedelics-investing MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform
psychedelics-investing MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board
psychedelics-investing MindMed Increases Cash on Hand to CAD $205.2m , Closes Financing of CAD $19.5m
psychedelics-investing MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company
psychedelics-investing MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
psychedelics-investing MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
psychedelics-investing The Future of Mental Health and Addiction Therapy: Why Capital is Flowing into Psychedelics
